ArticleEuropean journal of nuclear medicine and molecular imaging2010
Clinical impact of (11)C-methionine PET on expected management of patients with brain neoplasm.
Article in European journal of nuclear medicine and molecular imaging, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Radiological diagnosis of brain radiation necrosis after cranial irradiation for brain tumor: a systematic review.Radiation oncology (London, England) · 2019Pooled it
- Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality?Journal of neuro-oncology · 2013Pooled it
- Role of methionine metabolism in cancer: recent advances in molecular mechanisms and therapeutic implications.Experimental hematology & oncology · 2026Review
- Added value of [European journal of nuclear medicine and molecular imaging · 2023Article
- Impact ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Determination of brain tumor recurrence usingCancer science · 2021Article
- Article
- Can the function of the tubarial glands be evaluated using [EJNMMI research · 2021Article
- Current Radiopharmaceuticals for Positron Emission Tomography of Brain Tumors.Brain tumor research and treatment · 2018Review
- Visual and semiquantitative 11C-methionine PET: an independent prognostic factor for survival of newly diagnosed and treatment-naïve gliomas.Neuro-oncology · 2018Article
- Magnetic Resonance Spectroscopy, Positron Emission Tomography and Radiogenomics-Relevance to Glioma.Frontiers in neurology · 2018Review
- Prospective study ofBMC cancer · 2017Article
- Non-invasive metabolic imaging of brain tumours in the era of precision medicine.Nature reviews. Clinical oncology · 2016Review
- A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosisNeuro-oncology practice · 2016Article
- Imaging biomarkers in primary brain tumours.European journal of nuclear medicine and molecular imaging · 2015Review
- Observational
- ACR Appropriateness Criteria® pre-irradiation evaluation and management of brain metastases.Journal of palliative medicine · 2014Review
- SPECT and PET serve as molecular imaging techniques and in vivo biomarkers for brain metastases.International journal of molecular sciences · 2014Review
- Malignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methods.Cancer management and research · 2014Review
- Value of 11C-methionine PET in imaging brain tumours and metastases.European journal of nuclear medicine and molecular imaging · 2013Review
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe retrospectively examined the clinical efficacy of (11)C-methionine positron emission tomography ((11)C-MET PET) in patients with brain neoplasm, especially whether the (11)C-MET PET changed the clinical management and whether the change was beneficial or detrimental.
methodsThis study reviewed 89 (11)C-MET PET scans for 80 patients (20 scans for initial diagnosis of brain tumor and 69 scans for differentiating tumor recurrence from radiation necrosis). Final diagnosis and the effect on the intended management were obtained from the questionnaire to the referring physicians or directly from the medical records. The diagnostic sensitivity, specificity, and accuracy for the (11)C-MET PET were evaluated. Regarding the management impact, the rate of scans that caused changes in intended management was also evaluated. Moreover, the occurrence of scans having detrimental diagnostic impact (DDI) and beneficial diagnostic impact (BDI) were evaluated.
resultsSensitivity, specificity, and accuracy of (11)C-MET PET was 87.8, 80.0, and 85.9%. The intended management was changed in 50.0% of the scans. DDI and BDI were observed in 4.3 and 36.2% of the total relevant scans, respectively.
conclusion(11)C-MET PET can provide useful information in initial diagnosis and differentiating tumor recurrence from radiation necrosis. The intended management was changed in half of the scans. Since a few cases did not receive the requisite treatment due to false-negative results of (11)C-MET PET, management decision should be made carefully, especially in the case of a negative scan.
Indexed as
Identifiers
19915838What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.